Drug Profile


Alternative Names: CCD-1042; Ganaxalone IV; Ganaxolone IV; gnx

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Purdue Pharma
  • Developer Marinus Pharmaceuticals; Purdue Pharma
  • Class Antiepileptic drugs; Antimigraines; Neuroprotectants; Pregnanes; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus; Infantile spasms; Fragile X syndrome; Epilepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy; Fragile X syndrome; Lennox-Gastaut syndrome; Postnatal depression
  • Phase I Status epilepticus
  • Preclinical Angelman syndrome
  • No development reported Post-traumatic stress disorders
  • Discontinued Infantile spasms; Migraine; Neuropathic pain; Partial epilepsies

Most Recent Events

  • 07 Aug 2017 Phase-II clinical trials in Postnatal depression in USA (PO) (Marinus Pharmaceuticals pipeline, August 2017)
  • 01 Aug 2017 Discontinued - Phase-II for Partial epilepsies (Adjunctive treatment) in India, Europe, Brazil (PO)
  • 01 Aug 2017 Discontinued - Phase-III for Partial epilepsies (Adjunctive treatment) in Russia, Australia, Poland, Germany, Bulgaria, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top